🚨 BREAKING Compound Tirzepatide News: Lilly Sues Mochi Health and Others!
Eli Lilly has filed lawsuits against four large telehealth companies including Mochi Health, Fella and Delilah, Willow Health Services, and Henry Meds. The claim? These platforms are selling unapproved versions of tirzepatide, the same active ingredient in Mounjaro and Zepbound. In this video, we break down what Lilly is saying, why these lawsuits matter, and what this means for patients who rely on affordable access to GLP 1 medications.
We also talk about Lilly’s claim that these companies are influencing prescribing decisions. From fast tracked patient evaluations to templated scripts that push compounded meds, Lilly is calling out what it says is a sales driven model that puts patient safety at risk.
As the FDA shortage status ends and the legal system kicks into gear, the future of compounded GLP 1 meds hangs in the balance. If you are a patient, provider, or advocate in this space, you need to understand what is happening.
#tirzepatide #lawsuit #EliLilly #compounds #mounjaro, Zepbound, GLP 1 medications, compounded tirzepatide, telehealth, Henry Meds, Mochi Health, FDA tirzepatide update, weight loss medication access, obesity treatment news
